Waters Corporation
Waters Corporation (WAT) designs and manufactures laboratory analytical instruments — notably high-performance liquid chromatography and mass spectrometry systems — used to separate, identify and quantify chemical compounds. Its products, consumables and services serve pharmaceutical, biotech, chemical, food-safety and environmental laboratories worldwide. Revenue typically comprises capital equipment sales and recurring aftermarket consumables and service contracts, which can provide resilient cash flow but remain sensitive to capital spending cycles. Waters benefits from a strong installed base, long product lifecycles and regulatory-driven demand in drug development and quality control. Key considerations for investors include exposure to global pharmaceutical investment, competition from other instrument makers, currency and supply-chain risks, and the ongoing need for R&D. Market cap: $20.79B. This is general information for education, not personalised advice; values can rise or fall and past performance is not a guide.
Why It's Moving
Waters Stock Holds Steady as Q3 Momentum and BD Merger Hype Fuel Optimism Amid Recent Dip
Waters Corporation's shares dipped slightly on December 11 but remain up significantly since its blockbuster Q3 earnings release six weeks ago, propelled by sales beats and raised 2025 guidance. Investors eye the transformative $17.5 billion merger with BD's Biosciences unit, set for Q1 2026, which promises combined sales exceeding $6.5 billion and enhanced market dominance in life sciences.
- Q3 sales hit $800 million, topping guidance and growing 8% year-over-year, with pharma surging 11-12% on instrument replacement cycles and biologics demand[1][2][5].
- Raised full-year 2025 outlook to 6.7-7.3% constant currency sales growth and $13.05-$13.15 non-GAAP EPS, signaling double-digit earnings expansion[1][2][4].
- Strategic $17.5B Reverse Morris Trust merger with BD advances swiftly, with integration planning mobilizing teams for day-one readiness and major synergy potential[3][4].
Waters Stock Holds Steady as Q3 Momentum and BD Merger Hype Fuel Optimism Amid Recent Dip
Waters Corporation's shares dipped slightly on December 11 but remain up significantly since its blockbuster Q3 earnings release six weeks ago, propelled by sales beats and raised 2025 guidance. Investors eye the transformative $17.5 billion merger with BD's Biosciences unit, set for Q1 2026, which promises combined sales exceeding $6.5 billion and enhanced market dominance in life sciences.
- Q3 sales hit $800 million, topping guidance and growing 8% year-over-year, with pharma surging 11-12% on instrument replacement cycles and biologics demand[1][2][5].
- Raised full-year 2025 outlook to 6.7-7.3% constant currency sales growth and $13.05-$13.15 non-GAAP EPS, signaling double-digit earnings expansion[1][2][4].
- Strategic $17.5B Reverse Morris Trust merger with BD advances swiftly, with integration planning mobilizing teams for day-one readiness and major synergy potential[3][4].
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Waters Corporation's stock with a target price of $372.85, indicating growth potential.
Financial Health
Waters Corporation is performing well with strong revenue, profits, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring WAT
Pharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketBeyond The Ozarks: Trusted Outdoor Brands
This carefully selected group of stocks represents established outdoor and drinkware brands poised for growth. Our professional analysts have identified these companies as potential beneficiaries of shifting consumer preferences toward trusted, premium products following Walmart's major safety recall.
Published: July 11, 2025
Explore BasketPure Water Plays: Investing in Trusted Alternatives
Following investigations into Nestlé's water filtration practices, consumers may seek more transparent water options. These carefully selected stocks represent companies that could benefit from this shift, from beverage competitors to water purification technology providers.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Aftermarket Revenue Strength
Consumables and service contracts create steady recurring income that can stabilise revenue, though instrument orders remain cyclical and can vary.
Pharma & Regulation Demand
Demand from drug development and regulatory testing supports long-term need for high-end instruments, but exposure to regulatory cycles and geographic shifts adds variability.
Innovation & Competition
Continued R&D keeps the product line competitive in high-precision analytics, yet heavy R&D spend and rival technologies present execution risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
